Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769951 | 0.90 | EPHX2 (0.56) | EPHX2MEN1KMT2ATSHRHTT | |
| SCHEMBL769863 | 0.88 | EPHX2 (0.56) | EPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL770872 | 0.88 | EPHX2 (0.53) | EPHX2ALDH1A1MEN1KMT2AFKBP1A | |
| SCHEMBL771381 | 0.87 | GBA1 (0.47) | EPHX2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL770472 | 0.85 | EPHX2 (0.51) | EPHX2ALDH1A1TSHRSMN1; SMN2FKBP1A | |
| SCHEMBL772465 | 0.84 | ALDH1A1 (0.46) | EPHX2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL770704 | 0.80 | KMT2A (0.49) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL772095 | 0.80 | EPHX2 (0.58) | EPHX2ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL770097 | 0.79 | KMT2A (0.48) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL771320 | 0.78 | NPC1 (0.41) | EPHX2ALDH1A1TSHRSMN1; SMN2FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | EPHX2 1153/4885ALDH1A1 142/4885MEN1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.